Definitive Healthcare Corp. (NASDAQ:DH) Receives $2.77 Average Price Target from Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have been assigned an average recommendation of “Hold” from the eight analysts that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $2.7667.

A number of research firms have commented on DH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, January 21st. Zacks Research raised Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Canaccord Genuity Group reduced their target price on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a report on Friday, February 27th. Finally, Stephens reduced their target price on Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Friday, February 27th.

Definitive Healthcare Price Performance

Shares of NASDAQ DH opened at $0.81 on Wednesday. Definitive Healthcare has a fifty-two week low of $0.81 and a fifty-two week high of $4.70. The business has a 50 day moving average price of $1.05 and a two-hundred day moving average price of $1.89. The company has a quick ratio of 1.64, a current ratio of 1.75 and a debt-to-equity ratio of 0.81. The firm has a market cap of $85.25 million, a PE ratio of -0.50, a price-to-earnings-growth ratio of 75.17 and a beta of 1.34.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, May 7th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.The company had revenue of $55.93 million for the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Sell-side analysts expect that Definitive Healthcare will post 0.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DH. AQR Capital Management LLC lifted its holdings in Definitive Healthcare by 56.7% during the 1st quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock worth $1,706,000 after buying an additional 213,562 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after purchasing an additional 7,404,363 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Definitive Healthcare by 166.0% in the 1st quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock worth $304,000 after purchasing an additional 65,597 shares during the last quarter. Creative Planning lifted its holdings in shares of Definitive Healthcare by 41.7% in the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after purchasing an additional 8,428 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Definitive Healthcare in the 2nd quarter worth approximately $4,247,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.